Several other equities analysts also recently issued reports on the stock. JPMorgan Chase & Co. reaffirmed an overweight rating on shares of Shire PLC in a research note on Monday, October 3rd. BNP Paribas reaffirmed an outperform rating and set a GBX 5,900 ($73.02) price target on shares of Shire PLC in a research note on Friday, September 30th. Goldman Sachs Group Inc. reaffirmed a conviction-buy rating and set a GBX 6,300 ($77.97) price target on shares of Shire PLC in a research note on Thursday, September 29th. HSBC dropped their price target on shares of Shire PLC from GBX 5,250 ($64.98) to GBX 5,200 ($64.36) and set a hold rating for the company in a research note on Wednesday, September 28th. Finally, Berenberg Bank reaffirmed a buy rating and set a GBX 5,800 ($71.78) price target on shares of Shire PLC in a research note on Tuesday, September 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of Buy and a consensus price target of GBX 5,828 ($72.13).
Shire PLC (LON:SHP) opened at 5171.00 on Thursday. The firm’s market capitalization is GBX 35.31 billion. The company has a 50-day moving average of GBX 5,001.78 and a 200-day moving average of GBX 4,587.48. Shire PLC has a 52 week low of GBX 2,707.19 and a 52 week high of GBX 5,377.00.
The company also recently declared a dividend, which was paid on Friday, October 7th. Investors of record on Thursday, September 8th were issued a dividend of GBX 3.51 ($0.04) per share. This represents a yield of 0.07%. The ex-dividend date of this dividend was Thursday, September 8th.
In other news, insider Dominic Blakemore purchased 133 shares of the business’s stock in a transaction that occurred on Friday, September 30th. The shares were acquired at an average cost of GBX 5,010 ($62.00) per share, for a total transaction of £6,663.30 ($8,246.66).
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.